Abstract Aim. Insulin degludec/liragultide (IDegLira) is a fixed-ratio co-formulation of insulin degludec (a basal insulin) and liraglutide (GLP-1RA). This study aimed to investigate clinical outcomes in people with type 2 diabetes (T2D) after initiating IDegLira treatment in a real-world setting in Colombia. Methods. SPIRIT is a non-interventional, single-arm, retrospective chart review study to assess clinical outcomes in people with Type 2 Diabetes (T2D). These patients were switched from basal insulin (with or without oral antidiabetics (OADs)) and initiated treatment with IDegLira a minimum of 26 ± 6 weeks before the data collection start date. We collected data from the medical records of 175 patients in 10 clinical centers across Colombia. Results. Compared with baseline, there was a significant reduction in HbA1c by 1.3% (95% [-CI] 1.6, -1.0) (p < 0.0001) after 26 ± 6 weeks of follow-up. The mean HbA1c at baseline was 9.1%, and the mean at the end of the study was 7.8%. In addition, IDegLira significantly reduced the absolute body weight by 1kg (95% [IC] -1.5, -0.5) ( p -value < 0.0001), from a mean of 76.1kg at baseline to 75.1kg after follow-up. The mean IDegLira dose at the end of the study was 21.3 U, and no severe hypoglycemic events were observed during the follow-up period. Conclusion. In real-world practice, initiating IDegLira in T2D patients previously treated with basal insulin (± OAD) was associated with improved glycemic control, reduced body weight, and reduced risk of hypoglycemia. Trial registration ClinicalTrials.gov #NCT05324462 First posted: April 12, 2022 Last update posted: November 9, 2022